肿瘤患者治疗前后外周血sIL-2R水平测定

sIL-2R Level Assay in Peripheral Blood of the Tumor Patient Before and After Treatment

目的：探讨恶性肿瘤患者治疗前后细胞免疫功能。方法：用双抗体夹心ＥＬＩＳＡ法检测４０例各类恶性肿瘤患者治疗前后血清ｓＩＬ－２Ｒ水平。结果：恶性肿瘤患者血清ｓＩＬ－２Ｒ水平为１５８５．９１±７５８．１５，显著高于正常人２３９．２２±８１．１３（Ｐ＜０．００１），经治疗６个月后（手术、放疗）各类肿瘤患者血清ｓＩＬ－２Ｒ较治疗前明显降低，值为６３６．２５±５７６．２５（Ｐ＜０．０５），但仍未降至正常水平。结论：血清ｓＩＬ－２Ｒ作为恶性肿瘤患者免疫功能的检测指标之一，对恶性肿瘤的诊断、治疗和预后的判断具有重要意义。

Objective: To study the immune function of the patients with carcinoma before and after treatment. Method: The serum soluble interleukin-2 receptor (sIL-2R) in 40 patients with various carcinomas was detected by sandwich ELISAwith double antibodies. Result: The level of sIL-2R in patients with carcinoma was 1 585.91±758.15 which was higher than that of controls of 239.22±81.13 (P<0.001), whereas there were significantly difference between the group after treatment and the group before treatment in patients with carcinoma. The level of sIL-2R in patients with carcinoma was reduced obviously after treatment, which was 636.25±576.25 (P<0.05). Conclusion: The test of sIL-2R is one of immune function in patients with carcinoma, it is important for the diagnosis, treatment and prognosis of carcinoma.